uBriGene
uBriGene is a world-class CRO & CDMO committed to driving innovation and accelerating biologics development from concept to commercialization.
Description
uBriGene is a global leader in advanced therapy medicinal products (ATMPs), offering comprehensive cell and gene therapy contract development and manufacturing organisation (CDMO) services.
Founded in 2015, uBriGene operates across North America and Asia, with its headquarters in Maryland, USA. The company provides end-to-end solutions for the development and manufacturing of cell and gene therapies, including preclinical studies, investigational new drug (IND) enabling, and commercialisation. Their state-of-the-art facilities and integrated technology platforms support the transformation of ATMP concepts into viable therapies.
Key Products and Services:
- Cell and Gene Therapy CDMO Services: Comprehensive services encompassing plasmid production, mRNA-LNP development, sgRNA synthesis, viral vector manufacturing (AAV, lentivirus, adenovirus), and cell therapy products such as CAR-T, CAR-NK, iPSC, and MSC.
- Analytical Development and Testing: Advanced analytical services to ensure product integrity and regulatory compliance, utilising state-of-the-art technologies and quality infrastructures.
- Cell and Gene Therapy CRO Services: Support for discovery and preclinical studies, including production services for plasmids, mRNA-LNP, sgRNA, and various viruses.
uBriGene's commitment to quality and innovation has established it as a trusted partner in the biopharmaceutical industry, dedicated to advancing the development and production of life-saving biologics and biosimilars